A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids

Not Applicable

Completed

• Conditions: Moderate to severe cancer pain; Cancer; Pain

• Registration Number: ISRCTN65155201
• Lead Sponsor: The Royal Marsden NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-03-29
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Patients must have a clinical or histological diagnosis of cancer
2. Patients whose pain is not controlled on Step 2 (weak opioid) analgesics (as defined by the WHO analgesic ladder) who clinically require a strong opioid
3. Patients must be over 18 years of age
4. Patients must be able to give written informed consent
5. Patients must be willing to undergo genetic screening

Exclusion Criteria

Current exclusion criteria as of 23/06/2011:
1. Patients with renal failure (1.5x ULN). These patients should be treated with alfentanil as per Palliative Care Clinical Guidelines
2. Patients must not currently be taking regular strong opioids
3. Patients requiring parenteral administration of opioids
4. Patients with predominantly incident pain
5. Patients with a clearly defined history of intolerance to morphine or oxycodone
6. Patients who are pregnant

Previous exclusion criteria:
1. Patients with renal failure (1.5 x upper limit of normal [ULN]). These patients should be treated with alfentanil as per palliative care guidelines.
2. Patients must not have been taking regular Step 3 analgesics in the last month
3. Patients requiring parenteral administration of opioids
4. Patients with predominantly neuropathic pain
5. Patients with predominantly incident pain
6. Patients with a clearly defined history of intolerance to morphine or oxycodone

Study & Design

• Study Type: Interventional
• Study Design: Not specified